Exact Sciences Corp Stock Price, News & Analysis

Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in several upcoming investor conferences in June 2022. Key events include:

• William Blair 42nd Annual Growth Stock Conference on June 6, 2022, at 3:40 p.m. ET in Chicago.
• Jefferies Healthcare Conference on June 8, 2022, at 1:00 p.m. ET in New York.
• Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022, at 6:20 p.m. ET in Rancho Palos Verdes.
• Nephron Liquid Biopsy Innovation Symposium on June 21, 2022, at 11:00 a.m. ET (virtual).

Exact Sciences Corp. (NASDAQ: EXAS) announced participation in the BofA Securities Healthcare Conference in Las Vegas on May 11, 2022, at 5:00 p.m. ET. Investors can access the webcast via the investor relations section of Exact Sciences' website. The company is focused on cancer diagnostics, developing tests like Cologuard and Oncotype to support patients throughout their cancer journey. Exact Sciences aims to provide innovative solutions for cancer screening and diagnosis.

Exact Sciences Corp. (NASDAQ: EXAS) announced that its Oncotype DX Breast Recurrence Score test has received the highest rating in the American Society of Clinical Oncology (ASCO) guidelines for quality of evidence. The updated guidelines expand the test's use for early-stage breast cancer patients, especially in postmenopausal women with positive lymph nodes and premenopausal patients with node-negative disease. The RxPONDER study, published in The New England Journal of Medicine, underpins this recommendation, indicating significant data supporting tailored chemotherapy decisions.

Exact Sciences Corp. (NASDAQ: EXAS) reported a 21% increase in total revenue for Q1 2022, reaching $486.6 million, compared to $402.1 million in Q1 2021. Excluding COVID-19 testing, revenue grew 24%, driven by a 28% increase in Screening revenue to $306.5 million and an 18% rise in Precision Oncology revenue to $152.6 million. Despite this growth, the company faced a net loss of $180.9 million or $1.04 per share.

The 2022 revenue outlook is raised to $1,985-$2,032 million, bolstered by strong Screening and Precision Oncology performance.

Exact Sciences Corp. (Nasdaq: EXAS) announced its first quarter 2022 financial results release scheduled for April 26, 2022, after U.S. market close. A conference call will follow at 5 p.m. ET to discuss these results and business developments. The company, recognized for its advanced cancer diagnostic tests, continues to innovate in the area of cancer screening and diagnostics.

Investors can access the live webcast through its website, with an archive available post-event for those unable to attend.

Katie Couric has partnered with Exact Sciences (NASDAQ: EXAS) to launch a year-long campaign called 'Mission to Screen,' aiming to raise awareness about colon cancer screening. The initiative emphasizes the importance of screening for all adults aged 45 and older, especially given the rising incidence of colon cancer in younger individuals. Cologuard, Exact Sciences' FDA-approved noninvasive test, is highlighted as a key screening option. Over 44 million Americans aged 45-plus remain unscreened, despite the critical role of early detection in improving treatment outcomes.

Exact Sciences Corp. (Nasdaq: EXAS) announced its participation in two upcoming investor conferences. The Cowen Health Care Conference will feature a fireside chat on March 7, 2022 at 9:50 a.m. ET, while the Raymond James Institutional Investors Conference will hold a fireside chat on March 8, 2022 at 4:00 p.m. ET. Webcasts can be accessed via the investor relations section of Exact Sciences' website.

Exact Sciences focuses on advanced cancer diagnostics, including Cologuard and Oncotype tests.

Exact Sciences Corp. (Nasdaq: EXAS) reported $473.8 million in revenue for Q4 2021, a 2% increase year-over-year, while total revenue for 2021 reached $1,767.1 million. Screening revenue grew 11% to $277.7 million, and Precision Oncology revenue rose 27% to $149.0 million. However, COVID-19 testing revenue fell 52% to $47.1 million. The net loss for Q4 was $220.6 million or $1.28 per share, improving from a loss of $418.3 million in the same quarter the previous year. For 2022, the company projects revenue between $1,975 and $2,027 million.

Exact Sciences Corp. (Nasdaq: EXAS) announced plans to release its fourth quarter 2021 financial results on February 22, 2022, after U.S. market close. This will be followed by a webcast and conference call at 5 p.m. ET to discuss the results and business developments. The company, known for its cancer diagnostic tests, continues to expand its product pipeline with a focus on addressing critical cancer challenges. Investors can access the webcast live on the company's website.